ECSP22049665A - M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC) - Google Patents

M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC)

Info

Publication number
ECSP22049665A
ECSP22049665A ECSENADI202249665A ECDI202249665A ECSP22049665A EC SP22049665 A ECSP22049665 A EC SP22049665A EC SENADI202249665 A ECSENADI202249665 A EC SENADI202249665A EC DI202249665 A ECDI202249665 A EC DI202249665A EC SP22049665 A ECSP22049665 A EC SP22049665A
Authority
EC
Ecuador
Prior art keywords
aavc
cancer
treatment
cell
prevention
Prior art date
Application number
ECSENADI202249665A
Other languages
English (en)
Inventor
Kanako Shimizu
Taku Yoshida
Masayuki KANKI
Shinichiro Fujii
Keisuke Ohsumi
Original Assignee
Riken
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Riken, Astellas Pharma Inc filed Critical Riken
Publication of ECSP22049665A publication Critical patent/ECSP22049665A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • User Interface Of Digital Computer (AREA)

Abstract

La presente invenci?n encuentra escala apropiadas de la dosis de α-GalCer cargado en la superficie de la c?lula aAVC, as? como la cantidad de α-GalCer cargado en la superficie de la c?lula aAVC, en una composici?n farmac?utica que contiene aAVC, las cuales se prefieren en t?rminos de garantizar la efectividad y seguridad en el tratamiento y prevenci?n de un c?ncer utilizando aAVC; y proporciona un m?todo efectivo y seguro para el tratamiento o prevenci?n de un c?ncer utilizando aAVC para el tratamiento efectivo y seguro de un c?ncer; y una composici?n farmac?utica que comprende a la misma, etc.
ECSENADI202249665A 2019-12-02 2022-06-24 M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC) ECSP22049665A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019217712 2019-12-02

Publications (1)

Publication Number Publication Date
ECSP22049665A true ECSP22049665A (es) 2022-08-31

Family

ID=76222356

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202249665A ECSP22049665A (es) 2019-12-02 2022-06-24 M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC)

Country Status (20)

Country Link
US (2) US11617790B2 (es)
EP (1) EP4070810A4 (es)
JP (2) JP6912765B1 (es)
KR (1) KR20220119029A (es)
CN (1) CN114929272A (es)
AR (1) AR122341A1 (es)
AU (1) AU2020398783A1 (es)
BR (1) BR112022010750A2 (es)
CA (1) CA3162121A1 (es)
CL (1) CL2022001458A1 (es)
CO (1) CO2022008737A2 (es)
CR (1) CR20220319A (es)
DO (1) DOP2022000109A (es)
EC (1) ECSP22049665A (es)
IL (1) IL293483A (es)
JO (1) JOP20220122A1 (es)
MX (1) MX2022006712A (es)
PE (1) PE20221421A1 (es)
TW (1) TW202134265A (es)
WO (1) WO2021112056A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5672647B2 (ja) * 2006-02-22 2015-02-18 独立行政法人理化学研究所 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010061930A1 (ja) 2008-11-28 2010-06-03 独立行政法人理化学研究所 CD1d及び標的抗原の共発現アロ細胞を用いた免疫療法
JP5672647B2 (ja) 2006-02-22 2015-02-18 独立行政法人理化学研究所 ＣＤ１ｄリガンドをパルスした、標的抗原及びＣＤ１ｄの共発現細胞による免疫療法
US20130189302A1 (en) * 2006-02-22 2013-07-25 Riken Immunotherapeutic method using artificial adjuvant vector cells that co-express cd1d and target antigen
JP2007261876A (ja) 2006-03-28 2007-10-11 Tdk Corp 誘電体粒子、誘電体磁器組成物およびその製造方法
KR101194265B1 (ko) 2008-12-01 2012-10-29 주식회사 한국인삼공사 해양심층수를 이용하여 인삼 또는 홍삼 농축액의 고미 제거방법
KR20130018778A (ko) 2010-03-25 2013-02-25 쓰리엠 이노베이티브 프로퍼티즈 컴파니 복합 층
WO2013018778A1 (ja) 2011-07-29 2013-02-07 独立行政法人理化学研究所 ウィルムス腫瘍遺伝子産物またはその断片をコードしている改変型核酸構築物を含んでいる免疫治療用細胞、当該細胞の製造方法、および当該核酸構築物
US10316332B2 (en) * 2011-07-29 2019-06-11 Riken Cell for immunotherapy, including modified nucleic acid construct encoding Wilms tumor gene product

Also Published As

Publication number Publication date
WO2021112056A1 (ja) 2021-06-10
JOP20220122A1 (ar) 2023-01-30
CA3162121A1 (en) 2021-06-10
US11617790B2 (en) 2023-04-04
JP2021155443A (ja) 2021-10-07
CR20220319A (es) 2022-11-03
EP4070810A1 (en) 2022-10-12
BR112022010750A2 (pt) 2022-08-16
CL2022001458A1 (es) 2023-02-24
MX2022006712A (es) 2022-09-12
CO2022008737A2 (es) 2022-08-09
AU2020398783A1 (en) 2022-06-09
JP6912765B1 (ja) 2021-08-04
TW202134265A (zh) 2021-09-16
US20220016239A1 (en) 2022-01-20
US20230381305A1 (en) 2023-11-30
DOP2022000109A (es) 2022-10-16
JPWO2021112056A1 (ja) 2021-12-02
KR20220119029A (ko) 2022-08-26
IL293483A (en) 2022-08-01
CN114929272A (zh) 2022-08-19
AR122341A1 (es) 2022-09-07
EP4070810A4 (en) 2024-04-17
PE20221421A1 (es) 2022-09-20

Similar Documents

Publication Publication Date Title
ECSP22049665A (es) M?TODO PARA EL TRATAMIENTO DE C?NCER UTILIZANDO C?LULA ADYUVANTE ARTIFICIAL (aAVC)
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CO2017001493A2 (es) Kits que comprenden inhibidores tigit y agentes anticáncer
AR105712A1 (es) Composiciones de insulina de rápida acción
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
ECSP18073366A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
ECSP19083621A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
ECSP19070369A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2020013600A2 (es) Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak
PE20142362A1 (es) Agentes de iarn, composiciones y metodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
ECSP19070413A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR056801A1 (es) Terapia combinada anti- proliferativa con determinados agentes quimioterapeuticos basados en platino e inhibidores de egfr o analogos de pirimidina
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
CY1122968T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει μια ενωση διαμινο-ετεροκυκλικου καρβοξαμιδιου ως δραστικο συστατικο
CL2013003307A1 (es) Agente que comprende ciazofamida o fenamidona; y su uso para tratar micosis en peces e invertebrados en todos sus estadios de desarrollo causada por hongos de los generos saprolegnia, achlya y aphanomyces (div.sol.n°1056-08).
CO2017006983A2 (es) Una composición fungicida que comprende una n-ciclopropil- n-[bencilo sustituido]-3-(difluorometil)-5-fluoro-1- metil-1-h-pirazol-4-carboxamida o derivado de tiocarboxamida y dos compuestos fungicidas activos adicionales
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
CO2022000270A2 (es) Inhibidores de enzimas
WO2019018451A3 (en) COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING RADIATION-INDUCED PROXIMITY EFFECTS CAUSED BY RADIATION OR RADIATION THERAPY
BR112016016901A2 (pt) agentes para o uso no tratamento de inflamação retinal
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
BR112019004639A2 (pt) formulações de 4-metil-5-(pirazin-2-il)-3h-1,2-ditiol-3-tiona, formulações de gosto modificado e métodos para produzir e usar as mesmas
CO2021005872A2 (es) Composiciones y métodos para la estimulación ovárica controlada